Sorrento Therapeutics Inc
OTC:SRNE
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Sorrento Therapeutics Inc
Income from Continuing Operations
Sorrento Therapeutics Inc
Income from Continuing Operations Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Income from Continuing Operations | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Sorrento Therapeutics Inc
OTC:SRNE
|
Income from Continuing Operations
-$562.1m
|
CAGR 3-Years
-24%
|
CAGR 5-Years
-92%
|
CAGR 10-Years
-49%
|
|
|
Abbvie Inc
NYSE:ABBV
|
Income from Continuing Operations
$4.2B
|
CAGR 3-Years
-29%
|
CAGR 5-Years
-2%
|
CAGR 10-Years
-2%
|
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Income from Continuing Operations
$8.5B
|
CAGR 3-Years
23%
|
CAGR 5-Years
149%
|
CAGR 10-Years
-7%
|
|
|
Amgen Inc
NASDAQ:AMGN
|
Income from Continuing Operations
$7.7B
|
CAGR 3-Years
6%
|
CAGR 5-Years
1%
|
CAGR 10-Years
1%
|
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Income from Continuing Operations
$4B
|
CAGR 3-Years
6%
|
CAGR 5-Years
8%
|
CAGR 10-Years
N/A
|
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
Income from Continuing Operations
$4.5B
|
CAGR 3-Years
2%
|
CAGR 5-Years
5%
|
CAGR 10-Years
22%
|
|
Sorrento Therapeutics Inc
Glance View
Sorrento Therapeutics, Inc. engages in the research, development and manufacture of biopharmaceutical products. The company is headquartered in San Diego, California and currently employs 799 full-time employees. The company went IPO on 2007-01-19. The firm's segments include Sorrento Therapeutics and Scilex. The Sorrento Therapeutics segment is organized around Immune-Oncology therapeutic area, leveraging its G-MAB antibody library and targeted delivery modalities to generate cancer therapeutics. The Scilex segment is largely organized around its non-opioid pain management operations. Sorrento's immuno-oncology platforms include key assets such as fully human antibodies (G-MAB library), immuno-cellular therapies (DAR-T), antibody-drug conjugates (ADCs), and oncolytic virus (Seprehvec). Sorrento is also developing antiviral therapies and vaccines against coronaviruses, including Abivertinib, COVI-AMG, COVISHIELD, COVI-MSC and COVIDROPS; and diagnostic test solutions, including COVITRACK and COVISTIX.
See Also
What is Sorrento Therapeutics Inc's Income from Continuing Operations?
Income from Continuing Operations
-562.1m
USD
Based on the financial report for Jun 30, 2023, Sorrento Therapeutics Inc's Income from Continuing Operations amounts to -562.1m USD.
What is Sorrento Therapeutics Inc's Income from Continuing Operations growth rate?
Income from Continuing Operations CAGR 10Y
-49%
Over the last year, the Income from Continuing Operations growth was -7%. The average annual Income from Continuing Operations growth rates for Sorrento Therapeutics Inc have been -24% over the past three years , -92% over the past five years , and -49% over the past ten years .
